A Review of PARP-1 Inhibitors: Assessing Emerging Prospects and Tailoring Therapeutic Strategies
Drug Res (Stuttg) DOI: 10.1055/a-2181-0813Eukaryotic organisms contain an enzyme family called poly (ADP-ribose)
polymerases (PARPs), which is responsible for the poly (ADP-ribosylation) of
DNA-binding proteins. PARPs are members of the cell signaling enzyme class.
PARP-1, the most common isoform of the PARP family, is responsible for more than
90% of the tasks carried out by the PARP family as a whole. A
superfamily consisting of 18 PARPs has been found. In order to synthesize
polymers of ADP-ribose (PAR) and nicotinamide, the DNA damage nick monitor
PARP-1 requires NAD+ as a substrate. The capability of PARP-1 activation
to boost the transcription of proinflammatory genes, its ability to deplete
cellular energy pools, which leads to cell malfunction and necrosis, and its
involvement as a component in the process of DNA repair are the three
consequences of PARP-1 activation that are of particular significance in the
process of developing new drugs. As a result, the pharmacological reduction of
PARP-1 may result in an increase in the cytotoxicity toward cancer cells. [...] Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart,
GermanyArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Drug Research - Category: Drugs & Pharmacology Authors: Ramesh, Soundarya Almeida, Shannon D Hammigi, Sameerana Radhakrishna, Govardan Katta Sireesha, Golla Panneerselvam, Theivendren Vellingiri, Shangavi Kunjiappan, Selvaraj Ammunje, Damodar Nayak Pavadai, Parasuraman Tags: Review Source Type: research